D-1501-2016 Class III Terminated
FDA drug recall D-1501-2016 was initiated by Amerisource Health Services on Aug 4, 2016 and is designated Class III. Reason for recall: Failed dissolution specifications - the out of specification result for dissolution was identified during 3 month stability testing. The recall status is terminated (terminated Jul 17, 2017). Affected quantity: 2626 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Sep 21, 2016
- Initiation Date
- Aug 4, 2016
- Termination Date
- Jul 17, 2017
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 2626 bottles
Product description
buPROPion Hydrochloride Extended-Release Tablets, USP (XL), 300mg, 500-count bottle, Rx only, Manufactured by: Cadila Healthcare Ltd., Ahmedabad, India For BluePoint Laboratories, NDC 68001-264-03
Reason for recall
Failed dissolution specifications - the out of specification result for dissolution was identified during 3 month stability testing.
Distribution pattern
Nationwide and Puerto Rico
Code information
Lot #: MS1509, Exp 12/17
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1501-2016
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026